期刊
ANNALS OF ONCOLOGY
卷 22, 期 11, 页码 2516-2522出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdq784
关键词
histone deacetylase; pharmacodynamics; pharmacokinetics
类别
资金
- S*Bio
- National Medical Research Council [NMRC/TCR/001-NUH/2007)]
- Singapore Cancer Syndicate [SCS-PN0022]
Background: The objective of this study was to assess the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of SB939, a novel histone deacetylase (HDAC) inhibitor, in patients with advanced solid malignancies. Patients and methods: Dose-escalating cohorts of three to six patients received SB939 orally thrice weekly for 3 weeks in a 4-week cycle. Acetylated histone H3 (acH3) was measured in peripheral blood mononuclear cells (PBMCs). Results: Thirty patients treated at one of five doses (10-80 mg/day) received 79 cycles of SB939 (range, 1-12 cycles). Dose-limiting toxic effects were fatigue, hypokalemia, troponin T elevation, and QTc prolongation. Peak plasma concentration (C-max) and area under the concentration-time curve extrapolated to infinity increased dose proportionally. The MTD of SB939 was 80 mg/day. The mean elimination half-life and oral clearance of SB939 were 7.2 +/- 6 0.6 h and 53.0 +/- 6 8.5 l/h, respectively, with no substantial accumulation on day 15. An increase in acH3 was observed at hour 3 and correlated with dose and C-max. Stable disease was seen in several tumor types treated at >= 40 mg. HDAC inhibition was consistently observed at 60 mg, the recommended dose. Conclusions: SB939 can be safely administered at the recommended dose and reaches plasma levels that strongly inhibit HDAC in PBMCs. These data support further efficacy studies of SB939.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据